The global insulin patch pumps market is anticipated to grow at a CAGR of 15.2% during the forecast period (2023-2030). The market for insulin patch pumps is expanding owing to the increasing adoption of these pumps among people suffering from diabetes in developing countries. This has further encouraged market players to emphasis on R&D of technologically advanced products and pushed FDA approvals in the market. These R&D projects and FDA approvals have been accompanied by various clinical trials, showing evidence of sustained improvement in control of diabetic patients on pump therapy compared to those on MDI therapy. These pumps offer distinct clinical benefits and are equipped with advanced technologies. These include smartphone connectivity, integrated CGM sensors, and other features for the effective management of diabetes. These advantages are boosting the popularity of these pumps among healthcare professionals and patients suffering from diabetes globally. For instance,
Browse the full report description of “Insulin Patch Pumps Market Size, Share & Trends Analysis Report by type (Disposable and Reusable), and by Distribution Channel (Hospitals, Private Clinics, Retail Pharmacies and Others), Forecast Period (2023-2030)” at https://www.omrglobal.com/industry-reports/insulin-patch-pump-market
• In August 2023, Roche Diabetes Care, Inc.¸ obtained the 510(k) clearance for the Accu-Chek Solo® micropump system from the US FDA. This marked a substantial objective in continuous subcutaneous insulin infusion therapy (CSII) for people living with diabetes given the clinical significance of insulin pumps in daily diabetes management.
• In April 2023, Insulet Corp., the pioneer in tubeless insulin pump technology with its Omnipod® brand of products, received the FDA clearance of its product launch, Omnipod GO™, an insulin delivery device cleared for use for people with type 2 diabetes age 18 or older who would typically take daily injections of long-acting insulin. Omnipod GO is a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.
• In April 2023, Medtronic plc attained FDA approval for long-delayed MiniMed 780G insulin pump. The MiniMed™ 780G system is designed with SmartGuard™ technology, an advanced algorithm that uses current and past sugar level trends to anticipate, adjust, and correct insulin delivery.
Market Coverage
• The market number available for – 2022-2030
• Base year- 2022
• Forecast period- 2023-2030
• Segment Covered-
o By Type
o By Distribution Channel
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- includes, F. Hoffmann-La Roche Ltd, Medtronic plc., Terumo Corp., Tandem Diabetes Care Inc., and Abbott Laboratories, among others.
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Insulin Patch Pumps Market Report Segment
By Type
By Distribution Channel
Global Insulin Patch Pumps Market Report Segment by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/insulin-patch-pump-market